<DOC>
	<DOCNO>NCT00955916</DOCNO>
	<brief_summary>The purpose study find effect ( good bad ) Gleevec® ( Imatinib mesylate ) combine chemotherapy participant acute myeloid leukemia .</brief_summary>
	<brief_title>CLAG Gleevec Relapsed Refractory Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>In relapse resistant acute myeloid leukemia ( type blood cancer immature blood cell increase , block normal blood cell production ) , different type chemotherapy use treatment . Patients respond chemotherapy similar way , response last long stem cell transplantation do . Gleevec believe work interfere abnormal protein block tell body keep make white blood cell abnormal . The CLAG regimen standard chemotherapy use relapse AML ( Acute Myeloid Leukemia ) . This study add Gleevec® regimen period 14 day . Gleevec® approve Food Drug Administration ( FDA ) treatment chronic myeloid leukemia ( CML ) type acute lymphoblastic leukemia ( ALL ) . Its use combination CLAG regimen consider experimental treatment Acute Myeloid Leukemia/CML blast crisis .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Men Women ethnic group whose age ≥ 18 year old . Diagnosis AML CML blast crisis , accord World Health Organization ( WHO ) criterion , except acute promyelocytic leukemia AMLM3 FrenchAmericanBritish ( FAB ) subgroup . A documentation relapse require bone marrow/aspirate within 4 week registration . Refractory Relapsed AML . Refractory AML define failure achieve CR 2 cycle induction chemotherapy persistent ( &gt; 40 % ) bone marrow blast one cycle chemotherapy induction . Relapsed AML define evidence disease recurrence achieve complete response ( CR ) ( 5 % myeloblast ) . Early relapse define occur within 12 month late relapse defines occur 12 month . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Patients must sign write informed consent . Females childbearing potential ( FOCP ) must pregnant actively nursing child . They must negative pregnancy test 7 day initiation study drug administration Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female reproductive potential must agree employ effective barrier method birth control throughout duration trial 3 month follow study medication discontinuation . Prior allogeneic autologous stem cell transplantation allow . Abnormal Kidney Functions : creatinine ≥2.5 mg/dL . Abnormal Liver Functions : Bilirubin 3 mg/dL , transaminase ( AST/ALT ) 2.5 time institutional upper limit normal ( IULN ) . Systemic active infection , unless control active therapy . Patients Grade III/IV cardiac problem define New York Heart Association ( NYHA ) Criteria ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) , ejection fraction ( EF ) &lt; 30 % . Patient know chronic liver disease ( i.e. , chronic active hepatitis , hepatitis B , hepatitis C , cirrhosis ) . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . History malignancy , except nonmelanotic skin cancer disease recurrence/progression 2 year . Patients receive investigational agent within 1 month study entry . History allergic reaction attribute compound similar chemical biologic composition Gleevec component CLAG regimen Prior therapy CLAG chemotherapy regimen Any adverse event attributable previous chemotherapy regimen must resolve grade 1 less time registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>acute</keyword>
	<keyword>myeloid</keyword>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
	<keyword>blast crisis</keyword>
</DOC>